Novo Nordisk is expanding its biopharma business by acquiring the US and Canadian rights to Macrilen from Strongbridge Biopharma.
Macrilen (macimorelin) is the first and only FDA-approved oral growth hormone receptor indicated for the diagnosis of Adult Growth Hormone Deficiency (AGHD) – a rare endocrine disorder.
Novo Nordisk will pay $145 million upfront for the rights as well as tiered royalties related to sales of Macrilen.
Strongbridge’s current field organisation will continue to promote Macrilenin the US for up to three-year agreement.
The transaction is expected to close in December 2018.